Publicaciones en colaboración con investigadores/as de University Medical Center Hamburg-Eppendorf (15)

2024

  1. Correction: Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report (International Journal of Mental Health and Addiction, (2023), 10.1007/s11469-023-01213-9)

    International Journal of Mental Health and Addiction

  2. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study

    Journal of Allergy and Clinical Immunology, Vol. 153, Núm. 1, pp. 275-286.e18

  3. Tuberculosis Disease in Immunocompromised Children and Adolescents: A Pediatric Tuberculosis Network European Trials Group Multicenter Case-control Study

    Clinical Infectious Diseases, Vol. 79, Núm. 1, pp. 215-222

2023

  1. Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

    The Lancet Child and Adolescent Health, Vol. 7, Núm. 10, pp. 718-727

  2. Opioid Agonist Maintenance Treatment Outcomes—The OPTIMUS International Consensus Towards Evidence-Based and Patient-Centred Care, an Interim Report

    International Journal of Mental Health and Addiction

2022

  1. A Multi‑Center, Open‑Label, Single‑Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency

    Journal of Clinical Immunology, Vol. 42, Núm. 3, pp. 500-511

2021

  1. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

    New England Journal of Medicine, Vol. 385, Núm. 27, pp. 2531-2543

  2. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label phase 3 study

    Vaccine, Vol. 39, Núm. 20, pp. 2800-2809

2020

  1. Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations

    Journal of Allergy and Clinical Immunology, Vol. 146, Núm. 4, pp. 901-911

2017

  1. Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

    Journal of Pediatrics, Vol. 189, pp. 72-78.e3

  2. Progressive deafness–dystonia due to SERAC1 mutations: A study of 67 cases

    Annals of Neurology, Vol. 82, Núm. 6, pp. 1004-1015

2016

  1. Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

    RMD Open, Vol. 2, Núm. 1

2006

  1. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease

    Brain, Vol. 129, Núm. 9, pp. 2278-2287

2003

  1. Inter-laboratory comparison of HCV-RNA assay results: Implications for multi-centre research

    Journal of Medical Virology, Vol. 69, Núm. 2, pp. 195-201

2001

  1. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus: European Paediatric Hepatitis C Virus Network

    British Journal of Obstetrics and Gynaecology, Vol. 108, Núm. 4, pp. 371-377